Tolvaptan
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Tolvaptan
Tolvaptan: Renal-hepatic-pancreatic dysplasia
One-Sentence Summary
Tolvaptan is a vasopressin V2 receptor antagonist, originally used for inappropriate ADH syndrome (SIADH), nephrogenic syndrome of inappropriate antidiuresis, and polycystic kidney disease. The TxGNN model predicts it may be effective for renal-hepatic-pancreatic dysplasia, with no registered clinical trials but 20 publications (including 2 Phase 3 RCT reports, TEMPO 3:4 and REPRISE) currently supporting this direction. Most of this evidence comes from ADPKD, not from the PKD3 subtype itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Renal-hepatic-pancreatic dysplasia |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 12 of 12) |
| Number of DINs | 12 (marketed: 12) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Tolvaptan is a selective vasopressin V2 receptor antagonist. In polycystic kidney disease, vasopressin-driven cAMP signalling in renal tubular cells promotes cyst growth and fluid secretion. Blocking the V2 receptor lowers cAMP and slows cyst expansion. (The data compiled for this report does not include a formal mechanism-of-action entry; this description comes from the repurposing rationale and the published literature.)
Polycystic kidney disease is already among tolvaptan’s original indications, so this prediction is largely on-label rather than true repurposing. The specific PKD3 subtype (GANAB-related) has not been tested directly. The evidence comes from ADPKD (PKD1/PKD2) and is extrapolated through the shared cystogenic cAMP pathway. Tolvaptan’s effect on polycystic liver disease is not established.
Clinical Trial Evidence
Currently no related clinical trials registered for this predicted indication. The pivotal Phase 3 trials (TEMPO 3:4 and REPRISE) appear in the literature table below as published reports.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23121377 | 2012 | RCT (TEMPO 3:4, Phase 3) | N Engl J Med | Tolvaptan in early ADPKD; V2 antagonists inhibit cyst growth and slow decline in kidney function |
| 29105594 | 2017 | RCT (REPRISE, Phase 3) | N Engl J Med | Tolvaptan in later-stage ADPKD; earlier trial had shown liver enzyme elevations |
| 39356039 | 2024 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Interventions for preventing ADPKD progression |
| 40126492 | 2025 | Review | JAMA | ADPKD overview; most common inherited kidney disorder |
| 41771281 | 2026 | Review | Lancet | Strong evidence base for tolvaptan as disease-modifying treatment in high-risk patients |
| 40844441 | 2025 | Review (Core Curriculum) | Am J Kidney Dis | Disease-modifying therapy recommended for patients at risk of progression |
| 40726372 | 2025 | Review | Curr Opin Nephrol Hypertens | Tolvaptan remains the only FDA-approved therapy targeting progression; pipeline reviewed |
| 35487607 | 2022 | Review | Clin Liver Dis | Tolvaptan may slow renal function decline and cyst growth in ADPKD with polycystic liver disease |
| 32392574 | 2021 | Review | Pediatr Res | Tolvaptan use in adolescents and young adults with rapidly progressing ADPKD |
| 33376103 | 2020 | Commentary | Clin J Am Soc Nephrol | Long-term safety of tolvaptan in ADPKD |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02437538 | JINARC | Not recorded | Not recorded |
| 02491583 | JINARC | Not recorded | Not recorded |
| 02491575 | JINARC | Not recorded | Not recorded |
| 02370468 | SAMSCA | Not recorded | Not recorded |
| 02557193 | LUPIN-TOLVAPTAN | Not recorded | Not recorded |
Twelve valid single-ingredient licences exist in total (JINARC, SAMSCA and LUPIN-TOLVAPTAN); the five above are shown.
Safety Considerations
- Drug Interactions: 100 interactions were identified. Among those listed, the one rated Major is clarithromycin. Moderate-level interactions include aprepitant, dexamethasone, empagliflozin, miconazole, naltrexone, rolapitant, and several potassium supplements (potassium chloride, citrate, bicarbonate, gluconate).
- Disease-related contraindication signals (from the knowledge graph, not label text): liver failure, cirrhosis of the liver, substance abuse/dependence, active peptic ulcer disease, and demyelinating disease.
- Literature-based concerns: liver enzyme and bilirubin elevations were seen in the TEMPO 3:4 setting, so liver monitoring is warranted. Aquaresis-related adverse effects are expected from the mechanism.
Please also refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two Phase 3 RCT publications (TEMPO 3:4 and REPRISE) and a Cochrane review support tolvaptan in ADPKD, and polycystic kidney disease is already among its original indications. However, the PKD3 (GANAB-related) subtype has not been tested directly, and the liver signal requires careful management.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (currently missing and blocking safety screening)
- Approved indication text and dosage forms for the Canadian licences
- Formal mechanism-of-action data from DrugBank
- Subtype-specific (PKD3/GANAB) evidence, and evidence on polycystic liver disease
- A liver-function monitoring plan and confirmation of rapidly progressing disease before use
Other Predicted Indications (Brief Note)
The remaining nine predictions (renal-hepatic-pancreatic dysplasia, karyomegalic interstitial nephritis, thoracic malformation, Joubert syndrome with renal defect, nephronophthisis-spastic quadriparesia syndrome, hypertrichosis disorders, odontal/periodontal malformation syndrome, and Dandy-Walker syndrome) have no trials and little or no relevant literature. Most are rated Hold, and Joubert syndrome with renal defect is flagged as a research question needing preclinical work first.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.